NEW YORK, Sept. 11, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits can be filed on behalf of shareholders of Co-Diagnostics, Inc. CODXAmpio Pharmaceuticals, Inc. AMPESinovac Biotech Ltd. SVAand Lottery.com, Inc. LTRY LTRYW))). Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.

Co-Diagnostics, Inc. CODX

Class Period: May 12, 2022 – August 11, 2022

Lead Plaintiff Deadline: October 17, 2022

On August 11, 2022, Co-Dx shocked investors when the company issued a press release and filed a report with the Securities and Exchange Commission, disclosing its financial results for the quarter ended June 30, 2022. The company reported revenue of $5.0 million for the quarter ended June 30, 2022, compared to $27.4 million for the same period last year, a decrease of nearly 82%. The company attributed the decline primarily to lower demand for the Logix Smart™ COVID-19 test.

As a result of this news, the price of Co-Dx common stock fell $1.98 per share, or 30.65%, to close at $4.48 per share on August 12, 2022.

The lawsuit alleges that the defendants made false and/or misleading statements and/or failed to disclose the following: (1) Co-Diagnostics experienced a significant drop in demand for Logix Smart^TM COVID-19 test and demand for his Logix Smart^TM COVID-19 testing had declined sharply for the full quarter ended June 30, 2022; and (2) as a result, Defendant’s positive comments regarding demand for its Logix Smart^TM COVID-19 test lacked a sound basis. As the true details emerged, the lawsuit alleges that investors suffered damage.

For more information on the Co-Dx class action go to: https://bespc.com/cases/CODX

Ampio Pharmaceuticals, Inc. AMPE

Class Period: December 29, 2020 – August 3, 2022

Lead Plaintiff Deadline: October 17, 2022

The action takes place…